BiotechTube
Aura Biosciences

Aura Biosciences

AURA
United States

Aura Biosciences is leveraging its proprietary Virus-Like Drug Conjugate (VDC) platform to develop targeted therapies for solid tumors, with an initial focus on ocular and urologic oncology. The company's lead program targets choroidal melanoma, a rare cancer where current radiotherapy treatments often lead to severe vision loss and poor long-term survival. Aura's approach aims to transform cancer treatment by enabling precise tumor targeting while sparing healthy tissue, potentially offering a vision-preserving alternative to existing standards of care.

aurabiosciences.com

AURA · Stock Price

USD 6.31+0.32 (+5.34%)
Market Cap: $422.9M

Historical price data

AI Company Overview

Aura Biosciences is leveraging its proprietary Virus-Like Drug Conjugate (VDC) platform to develop targeted therapies for solid tumors, with an initial focus on ocular and urologic oncology. The company's lead program targets choroidal melanoma, a rare cancer where current radiotherapy treatments often lead to severe vision loss and poor long-term survival. Aura's approach aims to transform cancer treatment by enabling precise tumor targeting while sparing healthy tissue, potentially offering a vision-preserving alternative to existing standards of care.

OncologyOcular OncologyUrologic Oncology

Technology Platform

Virus-Like Drug Conjugate (VDC) platform utilizing Virus-Like Particles (VLPs) that can be conjugated with drugs or loaded with nucleic acids to create targeted therapies for solid tumors.

Pipeline

6
6 drugs in pipeline1 in Phase 3
DrugIndicationStageWatch
Bel-sarChoroidal MelanomaPhase 3
AU-011Eye CancerPhase 2
AU-011Uveal MelanomaPhase 2
Light-activated AU-011Uveal MelanomaPhase 1/2
AU-011Non-muscle-invasive Bladder CancerPhase 1

Funding History

4
Total raised:$160M
IPO$75MOct 21, 2021
Series C$45MMar 15, 2021
Series B$30MJun 15, 2018
Series A$10MJan 15, 2015

Opportunities

Aura's VDC platform has significant expansion potential beyond choroidal melanoma into other solid tumor types, particularly in urologic oncology and other cancers with high unmet need.
The platform's modular nature allows for development of multiple product candidates targeting different tumor types.
First-mover advantage in choroidal melanoma could establish the company as a leader in targeted ocular oncology.

Risk Factors

Clinical development risks are significant for this novel platform, particularly as a first-in-class approach.
Regulatory pathways for VDCs may be uncertain, and competition could emerge from other targeted therapy platforms.
The company's reliance on public markets for funding creates exposure to market volatility and investor sentiment.

Competitive Landscape

Aura faces limited direct competition in choroidal melanoma where no drug therapies are approved, but competes indirectly with radiotherapy providers. In the broader targeted oncology space, the company competes with ADC developers and other targeted therapy platforms. Differentiation may come from the VLP-based approach's potential advantages in tumor targeting and penetration.